SCHEMBL3522968

SCHEMBL3522968

Nc1ccc(F)c(-c2ccc(C(=O)CNc3ccc(F)c(Cl)c3)s2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
TSHR P16473 3/20 0.39
KMT2A Q03164 3/20 0.39
ERCC5 P28715 1/20 0.39
FEN1 P39748 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MGLL Q99685 1/20 0.39
MAPT P10636 2/20 0.39
ALOX15 P16050 1/20 0.39
FADS1 O60427 1/20 0.37
SLC2A1 P11166 1/20 0.37
ESRRG P62508 2/20 0.36
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
PLA2G1B P04054 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3522964 0.78 ERN1 (0.43) ALDH1A1KDM4EMAPTESRRGESR1
SCHEMBL3988281 0.72 ERN1 (0.49) ALDH1A1TSHRKDM4EMAPTESRRG
SCHEMBL29894695 0.68 FABP4 (0.56) ALDH1A1TSHRKMT2AKDM4EMAPT
SCHEMBL2728813 0.68 FABP4 (0.56) ALDH1A1TSHRKMT2AKDM4EMAPT
SCHEMBL2319841 0.68 KDM4E (0.56) ALDH1A1TSHRKMT2AKDM4EMGLL
SCHEMBL3531252 0.65 INPPL1 (0.38) TSHRKMT2AKDM4EMAPTCYP1A2
SCHEMBL28102406 0.65 KDM4E (0.60) ALDH1A1TSHRKMT2AKDM4EMAPT
SCHEMBL23617483 0.65 CYP3A4 (0.57) ALDH1A1TSHRKMT2AKDM4EMAPT
SCHEMBL5572694 0.64 SLC2A1 (0.73) ALDH1A1KMT2AMAPTFADS1SLC2A1
SCHEMBL3988284 0.63 BRD4 (0.36) DYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759366-B2 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2010-07-20 US disclosed
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use GPR119, GIPR, LIPC ALDH1A1 193/4885TSHR 872/4885KMT2A 1972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.